Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Bone Miner Metab ; 41(6): 854-864, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37897672

ABSTRACT

INTRODUCTION: To investigate the differences in the incidence rates of suspected stage 0/1 osteonecrosis of the jaw (ONJ) and incidence risk of relevant clinical findings of suspected stage 0 ONJ between patients treated with sequential therapy comprising weekly teriparatide for 72 weeks followed by alendronate for 48 weeks vs. those who received monotherapy with alendronate for 120 weeks. MATERIALS AND METHODS: Suspected stage 0/1 ONJ was defined by non-specific symptoms. Tooth mobility and periodontal symptoms (gingival bleeding, swelling, and/or pain) were selected as clinical findings of suspected stage 0 ONJ. Poisson regression models were applied to calculate the incidence rate ratios of suspected stage 0/1 between the teriparatide group (TG) and alendronate group (AG). Generalized linear models were used to calculate the risk ratios of clinical findings between groups. RESULTS: Two hundred and sixty-one participants in the TG and 344 in the AG answered a structured questionnaire on oral health and were included in this study. There were no significant differences between the groups in the incidence rate of suspected stage 0/1 ONJ at both 72 and 120 weeks. The risk ratio of the TG to AG for tooth mobility was 0.34 (95% confidence interval [CI] 0.13-0.88, p = 0.02) at 72 weeks and 0.90 (95% CI 0.40-2.03, p = 0.83) at 120 weeks. The incidence rate of tooth mobility related to periodontal symptoms decreased in the TG and increased in the AG during the study. CONCLUSION: Tooth mobility accompanied by clinical periodontal symptoms may be a useful early sign of stage 0 ONJ.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw , Bone Density Conservation Agents , Osteoporosis , Tooth Mobility , Humans , Alendronate/adverse effects , Bisphosphonate-Associated Osteonecrosis of the Jaw/epidemiology , Bone Density Conservation Agents/adverse effects , Diphosphonates/adverse effects , East Asian People , Osteoporosis/drug therapy , Osteoporosis/epidemiology , Osteoporosis/complications , Reproducibility of Results , Teriparatide/adverse effects , Tooth Mobility/chemically induced
2.
Biosci Biotechnol Biochem ; 81(1): 135-146, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27885938

ABSTRACT

Bacillus subtilis strains including the fermented soybean (natto) starter produce capsular polymers consisting of poly-γ-glutamate and levan. Capsular polymers may protect the cells from phage infection. However, bacteriophage ϕNIT1 carries a γ-PGA hydrolase gene (pghP) that help it to counteract the host cell's protection strategy. ϕNIT had a linear double stranded DNA genome of 155,631-bp with a terminal redundancy of 5,103-bp, containing a gene encoding an active levan hydrolase. These capsule-lytic enzyme genes were located in the possible foreign gene cluster regions between central core and terminal redundant regions, and were expressed at the late phase of the phage lytic cycle. All tested natto origin Spounavirinae phages carried both genes for capsule degrading enzymes similar to ϕNIT1. A comparative genomic analysis revealed the diversity among ϕNIT1 and Bacillus phages carrying pghP-like and levan-hydrolase genes, and provides novel understanding on the acquisition mechanism of these enzymatic genes.


Subject(s)
Bacillus Phages/genetics , Bacillus Phages/physiology , Bacillus subtilis/virology , Genomics , Glycoside Hydrolases/genetics , Polyglutamic Acid/analogs & derivatives , Soy Foods , Amino Acid Sequence , Bacillus Phages/enzymology , Bacillus subtilis/cytology , Bacillus subtilis/metabolism , Capsules , Fermentation , Gene Expression Regulation, Viral , Genome, Viral/genetics , Glycoside Hydrolases/chemistry , Glycoside Hydrolases/metabolism , Polyglutamic Acid/metabolism , Solubility
SELECTION OF CITATIONS
SEARCH DETAIL
...